// App-Quantinova.ai

P210/P210 : Patient and Nurse Preferences for Sensoready® Autoinjector Pen Versus Other Autoinjectors in Multiple Sclerosis: Results from a Multicenter Survey

Researchers

Presenter

  • A. Ross

Principal Investigators

  • C. Besser

  • S. Naval

  • D. Stoneman

  • H. Gaunt

  • N. Barker

Medical Centers

  • Rush University Medical Center, Chicago, IL

  • Novartis Pharma AG, Basel, SWITZERLAND

  • Novartis Healthcare Private Limited, Hyderabad, INDIA

  • Adelphi Research, Bollington, UNITED KINGDOM

  • University College London, London, UK

Locations

  • United States

  • Switzerland

  • India

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • Avonex

  • Copaxone injection

  • Rebif Rebidose

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved